<DOC>
	<DOC>NCT02967055</DOC>
	<brief_summary>This exploratory study will fill a knowledge gap regarding the pharmacokinetic effects of isotretinoin on the etonogestrel (ENG) contraceptive implant.</brief_summary>
	<brief_title>The Effect of Isotretinoin on the Etonogestrel Contraceptive Implant</brief_title>
	<detailed_description>The Investigators will enroll only women with an etonogestrel contraceptive implant in place who are initiating isotretinoin therapy through their dermatologist. The Investigators will monitor the subjects serum etonogestrel concentration during isotretinoin therapy but no medications will be provided through this study. No medical devices will be inserted as part of this study either.</detailed_description>
	<mesh_term>Isotretinoin</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Etonogestrel</mesh_term>
	<criteria>Have a secondary form of nonhormonal contraception or abstain during isotretinoin therapy and four weeks afterwards Have at least two negative pregnancy tests at least 19 days apart prior to initiating isotretinoin therapy Have normal baseline laboratory evaluation including liver function tests, basic metabolic panel, and complete blood count Willing to abstain from taking any Vitamin A supplement during the study period Have a BMI &gt;= 18.5 Currently breastfeeding Known contraindications to isotretinoin Currently taking any known cytochrome P450 3A4 enzyme inducers or inhibitors</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>